Ghassan Safadi, MD
Allergy & Immunology · Toledo, OHNPI 1003813205
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.6% of the total across 280 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 24.6% of the total. 2025 is the largest year on record at $1,779, 3.6 times the $500 reported in 2019.
Across 280 payments — averaging $18.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$1K
- AstraZeneca$1K
- CSL Behring$380
- Genentech USA, Inc.$366
- Amgen$344
- Novartis$297
- plus $1K from 17 others
What the payments were for
- Consulting fees$822%
- Food & beverage$4,83993%
- Education$3076%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 63 | $1,288 |
| AstraZeneca | 58 | $1,090 |
| CSL Behring | 18 | $380 |
| Genentech USA, Inc. | 21 | $366 |
| Amgen | 21 | $344 |
| Novartis | 16 | $297 |
| Sanofi | 11 | $211 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $194 |
| Pfizer | 11 | $176 |
| Kaleo, Inc. | 9 | $136 |
| GSK | 8 | $121 |
| Blueprint Medicines Corporation | 3 | $95 |
| Boehringer Ingelheim | 5 | $91 |
| AbbVie | 4 | $90 |
| ADMA Biomanufacturing LLC | 8 | $82 |
| Grifols USA, LLC | 4 | $79 |
| Shire North American Group Inc | 2 | $48 |
| Hospira, Inc. | 2 | $47 |
| Phadia US Inc. | 2 | $29 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $17 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
How this compares
$5,228 in reported general payments places this provider in the 60th percentile of 128 allergy & immunology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 38 | $280,285 |
| HyqviaIgg/Hyaluronidase,recombinant | 30 | $247,609 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $115,070 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 12 | $109,093 |
| Dupixent PenDupilumab | 22 | $80,921 |
| TezspireTezepelumab-Ekko | 16 | $68,597 |
| Dupixent SyringeDupilumab | 17 | $68,054 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 59 | $58,966 |
| Breo ElliptaFluticasone/Vilanterol | 58 | $32,532 |
| Spiriva RespimatTiotropium Bromide | 42 | $31,351 |
| Advair HfaFluticasone Propion/Salmeterol | 46 | $23,311 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 64 | $15,483 |
| SymbicortBudesonide/Formoterol Fumarate | 51 | $15,376 |
| Epinephrine | 71 | $14,690 |
| Azelastine Hcl | 413 | $10,048 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid, Hyqvia, Cuvitru | $194 | $642,96481 claims |
| CSL BehringHizentra | $380 | $109,09312 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $121 | $91,497117 claims |
| AstraZenecaTezspire, Symbicort, Pulmicort Flexhaler | $1,090 | $88,79791 claims |
| Boehringer IngelheimSpiriva Respimat | $91 | $31,35142 claims |
| Hikma Pharmaceuticals USAEpinephrine | $16 | $14,69071 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 128 allergy & immunology providers in Ohio.
Other allergy & immunology in Toledo
- Adam UpdegraffToledo$379K
- Syed RehmanToledo$374K
- Sherlyana SurjaToledo$21K
- Sudhir RaoToledo$4K
- Justin GreiweCincinnati$1M
- Jonathan BernsteinCincinnati$810K
- Gordon MyersCincinnati$346K
- Nancy Wasserbauer KingstonRocky River$256K
- David LangCleveland$251K
- James FernandezCleveland$179K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.